

#### Ind-Swift Laboratories Limited

(A Recognised Export House) Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com CIN No. L24232CH1995PLC015553



Ref.: ISLL:CH:2024

Date: 7<sup>th</sup> February, 2024

The President, Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal Street, Mumbai 400001

ISIN: INE915B01019, INE915B07024 BSE Scrip Code: 532305, 957989 The Vice President, National Stock Exchange of India Limited, Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/2, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051

NSE Symbol: INDSWFTLAB

Sub: Intimation regarding Prior Disclosure received under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 from M/s. Essix Biosciences Limited

Respected Sir/Madam,

With reference to the captioned subject, please find herewith a disclosure under Regulation 10(5)-Intimation to stock exchanges in respect of proposed acquisition under Regulation 10(1)(a) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (as amended) as received by the Company from M/s. Essix Biosciences Limited.

This is for your information and records.

Thanking you, For IND-SWIFT LABORATORIES LTD.



PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY Encl: a/a

### **Essix Biosciences Limited**

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA) Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294 Factory : Plot No. B-4 & 5, Industrial Focal Point, Derabassi, Punjab (India) Ph. 01762-281278, 79. CIN NO. U74999CH1993PLC033428

Date: 07 February 2024

The Bombay Stock Exchange Limited	National Stock Exchange of India Limited		
Corporate Relations Department	Corporate Listing Department		
Floor 25, PJ Towers,	Exchange Plaza, 5 th Floor,		
Dalal Street	Bandra-Kurla Complex,		
Mumbai - 400 001	Bandra (E), Mumbai - 400 051		

#### Sub: Submission of Disclosure required under Regulation 10(5) of the SEBI (SAST) Regulations, 2011

Dear Sir/Madam,

I hereby submit the disclosure as required under Regulation 10(5) of the SEBI (SAST) Regulations, 2011, for acquisition of 94,99,720, (16.08%) equity shares held by Ind-Swift Limited in Ind-Swift Laboratories Limited.

This transaction, being an inter-se transfer of shares amongst the promoter group, falls within the exemptions provided under Regulation 1 O(1)(a)(ii) of the SEBI (SAST) Regulations, 2011. The Aggregate holding of Promoter and Promoter Group before and after the above inter-se transaction remains the same.

In this connection necessary disclosure under Regulation 10(5) in respect of above said acquisition in the prescribed format is enclosed herewith for your kind information and records.

Kindly take the same on your record and acknowledge the receipt of the same.

Yours truly

For Essix Biosciences Limited sumilea Pankai Company Secretary

Encl: as above

Cc: Ind-Swift Laboratories Limited Address: SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh,India-160101

## **Essix Biosciences Limited**

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA) Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294 Factory : Plot No. B-4 & 5, Industrial Focal Point, Derabassi, Punjab (India) Ph. 01762-281278, 79. CIN NO. U74999CH1993PLC033428

# Format for Disclosures under Regulation 10(5) - Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Terret O					
	and of the ranget company (TC)	IND SWIFT LABORATORIES LIMITED (ISLL)				
2.	and addance (3)	ESSIX BIOSCIENCES LIMITED (EPI)				
• 3.	of the TC prior to the transaction. If r nature of relationship or association v the TC or its promoters	ters YES, THE ACQUIRER IS A PROMOTER				
4.	Details of the proposed acquisition	5 C				
	<ul> <li>Name of the person(s) from whom shares areto be acquired</li> </ul>	IND SWIFT LIMITED (ISL)				
	<ul> <li>Proposed date of acquisition</li> </ul>	14/02/2024				
	c. Number of shares to be acquired from eachperson mentioned in 4(a) above	9499720				
	d. Total shares to be acquired as % of sharecapital of TC	16.08%				
	e. Price at which shares are proposed to be acquired	Price to be determined in compliance with regulation 10(1)(a) of the SEBI (SAST) Regulations, 2011.				
	f. Rationale, if any, for the proposed transfer	Inter-se Transfer				
5.	Relevant sub-clause of regulation 10(1)(a) Regulation 10(1)(a)(ii) under which the acquirer is exempted from making openoffer					
6.	If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC arerecorded during such period.					
7.	If in-frequently traded, the price a determined in terms of clause (e) of sub regulation (2) of regulation 8.	Not Applicable				
8.	acquisition price would not be ninner h	e Yes, we declare that the acquisition price y would not be higher by more than 25% n ofthe price computed in point 6 or point 7.				



## **Essix Biosciences Limited**

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA) Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294 Factory : Plot No. B-4 & 5, Industrial Focal Point, Derabassi, Punjab (India) Ph. 01762-281278, 79. CIN NO. U74999CH1993PLC033428

9	transferor and transferee have complie (during 3 years prior to the date of proposed acquisition) / will comply with	ansteror and transferee have complied luring 3 years prior to the date of roposed acquisition) / will comply with oplicable disclosure requirements in hapter V of the Takeover Regulations, 011 (corresponding provisions of the pealed Takeover Regulations, 1997). The aforesaid disclosures made during evious 3 years prior to the date of						
10	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.	It is hereby declared that all the conditions specified under Regulation 10(1)(a) with respect to exemptions have been duly complied with.						
11	Shareholding details	Before the proposed transaction		After the proposed transaction				
		No. of shares /voting rights	% w.r.t total share capital of TC	No. of shares /voting rights	% w.r.t total share capital			
	a Acquirer(s)	12827787	21.71%	22327507	of TC 37.79%			
	b PACs (other than sellers)	2491276	4.22%	2491276	4.22%			
	c Seller (s)	9499720	16.08%	0	0 %			

Signature of the Acquirer For Essix Biosciences Limited

Pankaj Company Secretary

Date- 07.02.2024 Place- Chandigarh